A new study led by Monash University has discovered that combining two widely used antibiotics can kill the dangerous bacterium Pseudomonas aeruginosa and stop it from spreading resistance to other drugs. This pathogen causes life-threatening infections such as bloodstream infections, pneumonia, and meningitis. The findings offer a promising approach to tackling a major global health threat.

  • Two common antibiotics, when used together, kill highly drug-resistant Pseudomonas aeruginosa.
  • The combination also prevents the bacterium from spreading its resistance genes to other bacteria.
  • Pseudomonas aeruginosa is a leading cause of hospital-acquired infections and is often resistant to multiple drugs.
  • This strategy could help preserve the effectiveness of existing antibiotics.

The growing threat of Pseudomonas aeruginosa

Pseudomonas aeruginosa is a bacterium that thrives in hospital settings and can cause severe infections in people with weakened immune systems. It is notoriously difficult to treat because it has developed resistance to many commonly used antibiotics. The World Health Organization has listed it as a priority pathogen for which new treatments are urgently needed. Current options are limited, and infections often lead to prolonged hospital stays and higher death rates.

An unusual antibiotic pairing

Researchers at Monash University tested combinations of existing antibiotics against strains of Pseudomonas aeruginosa that are resistant to multiple drugs. They found that a specific pairing of two antibiotics, which are normally used for different types of infections, worked together to kill the bacteria. According to the study, this combination was effective even against strains that had previously shown resistance to one of the drugs. The two antibiotics are already approved for human use, which simplifies the path to clinical application.

How the combination stops resistance

Beyond simply killing the bacteria, the dual therapy also prevented the spread of antibiotic resistance. Pseudomonas aeruginosa can share resistance genes with other bacteria through a process called horizontal gene transfer. The study found that the combination of drugs blocked this transfer mechanism. This means that not only are the bacteria killed, but the development and spread of resistance are also curtailed. The researchers noted that this dual action is rare and represents a major step forward in the fight against superbugs.

Implications for global health

The findings have significant implications for hospitals worldwide, where drug-resistant infections are a daily challenge. Because the two antibiotics are inexpensive and widely available, this strategy could be adopted in low- and middle-income countries that bear a disproportionate burden of antibiotic resistance. The researchers emphasize that more clinical trials are needed to confirm the safety and efficacy of the combination in patients, but the results offer hope for a practical solution to an urgent problem.

Frequently Asked Questions

What is Pseudomonas aeruginosa?

Pseudomonas aeruginosa is a type of bacteria commonly found in soil and water. In healthcare settings, it can cause serious infections in people with compromised immune systems, including those on ventilators or with surgical wounds. It is known for its ability to resist many antibiotics, making infections difficult to treat.

How does the combination therapy work?

The study showed that two antibiotics, when given together, attack the bacteria in complementary ways. One antibiotic disrupts the bacterial cell wall, while the other interferes with protein production. This dual attack not only kills the bacteria but also prevents them from passing resistance genes to other microbial cells.

Is this treatment available now?

Both antibiotics are already approved for medical use, so doctors could potentially prescribe them together for certain infections. However, the researchers caution that formal clinical trials are still needed to determine the optimal dosing and to confirm safety in patients. It is not yet a standard treatment protocol.

This is an original report by Vital Signs Today, informed by reporting from Medical Xpress. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.